Peptides MEX / Comparisons

MOTS-c vs tesamorelin: mitochondrial signaling and the GH axis

MOTS-c was identified as a peptide encoded within the mitochondrial genome; tesamorelin is a synthetic GRF analogue. Although both appear in metabolic research, mitochondrial signaling and pituitary stimulation describe distinct biological questions.

Updated 9 November 2026 · Sources and editorial standards

Key differences: MOTS-c / Tesamorelin
Feature	MOTS-c	Tesamorelin
Identity[1][2]	Mitochondrial-derived peptide	Synthetic GRF analogue
Mechanistic context[1][2]	Cellular metabolic regulation	GH/IGF-I axis stimulation
Human-evidence distinction[4][3]	Endogenous MOTS-c after exercise in the cited study	Visceral-fat trial in people with HIV

Mitochondrial origin versus a modified endocrine signal

The initial MOTS-c study described a 16-residue peptide associated with a short coding sequence within mitochondrial 12S ribosomal RNA. Tesamorelin retains the human GRF sequence with a chemical modification. MOTS-c is therefore not another version of the GHRH analogue and does not share its molecular identity.

Sources: [1][2]

Experimental metabolism and clinical visceral fat

Early MOTS-c experiments explored metabolic regulation in cells and mice, including insulin sensitivity. The cited tesamorelin trial measured visceral and liver fat in patients with HIV. One investigates mechanisms and model responses; the other compares body-composition outcomes against placebo in a defined clinical population.

Sources: [1][3]

Measuring MOTS-c after exercise is not testing an intervention

The 2021 study found endogenous MOTS-c changes after exercise in humans and tested peptide interventions in mice. Those components must be separated: observing a signal produced by the body does not demonstrate that an external material reproduces exercise. It also does not establish a comparison with tesamorelin for visceral fat.

Sources: [4][3]

Questions about this reference

Are both GH secretagogues?

Tesamorelin is described as a GRF analogue acting on the GH axis. The cited MOTS-c research addresses mitochondrial signaling and metabolic regulation, rather than identifying it as the same class of secretagogue.

[2][1]

Do mouse results predict human fat loss?

They generate hypotheses requiring human evaluation. In these sources, MOTS-c mouse interventions and the human tesamorelin trial have different populations, controls and endpoints.

[1][3]

Sources and original reading

Content updated: 9 November 2026. How this content is prepared and checked.